Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 4/20 | 0.48 |
| ▸ | CCR1 | P32246 | 9/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.43 |
| ▸ | PRCP | P42785 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4975063 | 1.00 | IDO1 (0.48) | IDO1CCR1DRD2BCL2L1MCL1 | |
| SCHEMBL600742 | 0.87 | ESR2 (0.49) | CYP2C9 | |
| SCHEMBL4976355 | 0.86 | SLC18A3 (0.47) | DRD2PRCP | |
| SCHEMBL1171605 | 0.86 | SLC18A3 (0.47) | DRD2PRCP | |
| SCHEMBL9408355 | 0.82 | IDO1 (0.42) | IDO1CCR1DRD2BCL2L1MCL1 | |
| SCHEMBL9408335 | 0.79 | IDO1 (0.40) | IDO1CCR1BCL2L1MCL1PRCP | |
| Acetic Acid SCHEMBL28980245 | 0.77 | IDO1 (0.49) | IDO1CCR1DRD2MAPTMEN1 | |
| Bicarbonate SCHEMBL1719769 | 0.77 | IDO1 (0.51) | IDO1DRD2BCL2L1MCL1MAPT | |
| SCHEMBL603381 | 0.77 | DRD2 (0.50) | IDO1DRD2CYP2C9 | |
| SCHEMBL5967397 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1646383-A4 | DESIGN AND SYNTHESIS OF OPTIMIZED LIGANDS FOR PPAR | BETHESDA PHARMACEUTICALS INC (US) | 2009-03-25 | — | — | EP | disclosed |
| US-7339065-B2 | Design and synthesis of optimized ligands for PPAR | BETHESDA PHARMACEUTICALS, INC. (US) | 2008-03-04 | — | — | US | disclosed |
| US-20070099969-A1 | Design and synthesis of optimized ligands for ppar | THE UNIVERSITY OF MISSISSIPPI | 2007-05-03 | — | — | US | disclosed |
| EP-1646383-A1 | DESIGN AND SYNTHESIS OF OPTIMIZED LIGANDS FOR PPAR | Bethesda Pharmaceuticals, Inc. (US) | 2006-04-19 | — | — | EP | disclosed |
| WO-2005009437-A1 | DESIGN AND SYNTHESIS OF OPTIMIZED LIGANDS FOR PPAR | BETHESDA PHARMACEUTICALS, INC. (US) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099969-A1 | Design and synthesis of optimized ligands for ppar | PPARD, PPARA, PPARG | IDO1 1860/4885CCR1 1500/4885DRD2 528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.